Sugi Predict

Sugi Predict / Compounds / SCHEMBL1634907

SCHEMBL1634907

SCHEMBL1634907

CCN(F)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ TSHR P16473 3/20 0.46
▸ GLA P06280 1/20 0.46
▸ MAPT P10636 3/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KMT2A Q03164 4/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ DRD1 P21728 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3323102 0.97 ALDH1A1 (0.45) ALDH1A1TSHRGLAMAPTCYP3A4
SCHEMBL10705258 0.81 TDP1 (0.44) ALDH1A1MAPTTDP1KDM4EKMT2A
SCHEMBL8066681 0.81 KCNH2 (0.44) ALDH1A1TSHRGLAMAPTCYP3A4
SCHEMBL9289298 0.80 TP53 (0.42) ALDH1A1TSHRGLAMAPTCYP3A4
SCHEMBL20221303 0.80 NPC1 (0.47) MAPTTDP1CHRM2HTR1AADRA2A
SCHEMBL2150314 0.78 ALDH1A1 (0.52) ALDH1A1TSHRGLAMAPTCYP3A4
SCHEMBL2065327 0.78 ALDH1A1 (0.40) ALDH1A1TSHRGLAMAPTCYP3A4
Fluoromethane SCHEMBL2149463 0.77 ALDH1A1 (0.57) ALDH1A1TSHRGLAMAPTCYP3A4
SCHEMBL29791060 0.77 ALDH1A1 (0.46) ALDH1A1TSHRMAPTCYP3A4TDP1
SCHEMBL27705430 0.76 ALDH1A1 (0.39) ALDH1A1TSHRGLAMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120018406-A Fine circuit pattern diffusion inhibitor and preparation method and application method thereof 深圳市板明科技股份有限公司 2025-05-16 — — CN claimed
CN-119923165-A Solar cell, preparation method thereof, photovoltaic module, system and power utilization device 宁德时代新能源科技股份有限公司 2025-05-02 — — CN claimed
CN-118853145-A Laser gain medium stable in air for long time and preparation method thereof 电子科技大学长三角研究院(衢州) 2024-10-29 — — CN claimed
CN-118614160-A Perovskite solar cell, preparation method thereof and power utilization device 宁德时代新能源科技股份有限公司 2024-09-06 — — CN claimed
CN-117202748-A Perovskite film and preparation method and application thereof 上海科技大学 2023-12-08 — — CN claimed
CN-117015252-A Solar cell with combined action of cesium salt and organic aromatic amine salt and preparation method thereof 电子科技大学 2023-11-07 — — CN claimed
CN-116963513-A Perovskite photovoltaic device preparation method based on micropore structure 中国科学技术大学 2023-10-27 — — CN claimed
EP-1144403-B1 SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS SEARLE LLC (US) 2004-10-06 — — EP claimed
CN-121604715-A Method for improving perovskite film quality by using high-polarity additive and application 吉林大学 2026-03-03 — — CN disclosed
CN-120018406-B Fine circuit pattern diffusion inhibitor and preparation method and application method thereof 深圳市板明科技股份有限公司 2025-08-05 — — CN disclosed
CN-120018406-A Fine circuit pattern diffusion inhibitor and preparation method and application method thereof 深圳市板明科技股份有限公司 2025-05-16 — — CN disclosed
CN-120018406-A Fine circuit pattern diffusion inhibitor and preparation method and application method thereof 深圳市板明科技股份有限公司 2025-05-16 — — CN disclosed
WO-2025091971-A1 SOLAR CELL AND PREPARATION METHOD THEREFOR, PHOTOVOLTAIC MODULE, SYSTEM, AND APPARATUS 宁德时代新能源科技股份有限公司 2025-05-08 — — WO disclosed
CN-119923165-A Solar cell, preparation method thereof, photovoltaic module, system and power utilization device 宁德时代新能源科技股份有限公司 2025-05-02 — — CN disclosed
US-20090137624-A1 anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine ASTRAZENECA AB (SE) 2009-05-28 — — US disclosed
CN-101304747-A Combinations comprising a VEGF receptor inhibitor and a penetration enhancer NOVARTIS AG (CH) 2008-11-12 — — CN disclosed
WO-2008016643-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 — — WO disclosed
CN-101018784-A Bicyclic amides as kinase inhibitors NOVARTIS AG (CH) 2007-08-15 — — CN disclosed
EP-1771443-A1 QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2007-04-11 — — EP disclosed
WO-2006002828-A1 QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2006-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137624-A1 anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine ERBB4, ERBB2, ABL1 ALDH1A1 1942/4885TSHR 2207/4885GLA 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.